Baxter Announces CEO Retirement and Appointment of COO
Baxter International Inc. (
NYSEBAX), a global medtech leader, today announced that José (Joe) E. Almeida, chair, president and chief executive officer (CEO), will retire from his executive roles with the company, effective immediately. He will serve in an advisory capacity through Oct. 31, 2025.
Baxter Kidney Care is Now Vantive, A New Standalone Vital Organ Therapy CompanyVantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options
Baxter to Host Fourth-Quarter 2024 Financial Results Conference Call for Investors
Baxter International Inc. (
NYSEBAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I2823858 to pre-register for the call and receive the call information.
Baxter to Present at 43rd Annual J.P. Morgan Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. José (Joe) E. Almeida, Baxter's chair, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time.
Baxter Announces Continued Growth of Pharmaceuticals Portfolio With Five Injectable Product Launches in the U.S.
Baxter International Inc. (
NYSEBAX), a global leader in injectables, anesthesia and drug compounding, today announced five new injectable pharmaceutical product launches in the U.S., joining the previous five launches announced in April of this year and marking a total of 10 U.S. injectable product launches in 2024.
Baxter to Present at 7th Annual Evercore HealthCONx Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the 7th Annual Evercore HealthCONx Conference on Thursday, December 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:10 a.m. Eastern Time.
Baxter to Present at Jefferies London Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 11:00 a.m. Greenwich Mean Time.
Baxter to Present at Stifel 2024 Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the Stifel 2024 Healthcare Conference on Monday, November 18, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:35 a.m. Eastern Time.
Baxter Declares Quarterly Dividend
Baxter International Inc. (
NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.17 per share of common stock. The dividend is payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share of common stock.
Baxter Reports Third-Quarter 2024 Results
Baxter International Inc. (
NYSEBAX), a global medtech leader, today reported results for the third quarter of 2024.
Baxter to Present at UBS Global Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the UBS Global Healthcare Conference on Wednesday, November 13, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:15 p.m. Pacific Time.
Baxter to Host Third-Quarter 2024 Financial Results Conference Call for Investors
Baxter International Inc. (
NYSEBAX), a global medtech leader, will host a conference call to discuss its third-quarter 2024 financial results on Friday, November 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/391655054 to pre-register for the call and receive the call information.
Baxter Provides Update on North Cove, N.C., Facility and Hurricane Helene Relief Plans for Community
Baxter International Inc. (
NYSEBAX), a global medtech leader, today shared updates regarding the impact of Hurricane Helene, which brought unprecedented rain and extensive flooding to Western North Carolina, on the operations of its North Cove facility in Marion, N.C.
Baxter Launches Next Generation of The Vest System for Airway Clearance
Baxter International Inc. (
NYSEBAX), a leading global medtech company, today unveiled its next generation airway clearance system, The Vest Advanced Pulmonary Experience (APX) System, at the North American Cystic Fibrosis Conference. The Vest APX System supports daily therapy for adults and children with certain chronic lung conditions and retained secretions. The system features the same trusted airflow technology as the previous version, with enhanced comfort and additional patient-centered features driven by clinician and patient input.
Baxter Appoints Jeffrey A. Craig to Its Board
Baxter International Inc. (
NYSEBAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief executive officer (CEO) of Meritor Corporation, to its board of directors. Mr. Craig will serve on Baxter’s Audit Committee. His appointment is effective today and brings the total number of directors serving the company to 12.
Baxter to Present at 2024 Wells Fargo Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 1:30 p.m. Eastern Time.
Baxter Announces Definitive Agreement to Divest Its Vantive Kidney Care Segment to Carlyle for $3.8 Billion
Baxter International Inc. (
NYSEBAX), a global medtech leader, and funds managed by global investment firm Carlyle
NASDAQ:CGNASDAQCG)
Baxter Reports Second-Quarter 2024 Results
Baxter International Inc. (
NYSEBAX), a global medtech leader, today reported results for the second quarter of 2024.
Baxter to Host Second-Quarter 2024 Financial Results Conference Call for Investors
Baxter International Inc. (
NYSEBAX), a global medtech leader, will host a conference call to discuss its second-quarter 2024 financial results on Tuesday, August 6, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I898552708 to pre-register for the call and receive the call information.
Baxter Declares Quarterly Dividend
Baxter International Inc. (
NYSEBAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.29 per share of common stock. The dividend is payable on Oct. 1, 2024, to stockholders of record as of Aug. 30, 2024. The indicated annual dividend rate is $1.16 per share of common stock.
Baxter publishes annual corporate responsibility report, highlighting continued focus on creating lasting impact
Baxter International Inc. (
NYSEBAX), a global medtech leader, today published its 2023 Corporate Responsibility Report. The annual report showcases Baxter’s dedication to making a meaningful difference in global healthcare and reporting with transparency on the environmental, social and governance topics most important to its stakeholders.
Baxter to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time.
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. (
NYSEBAX), a global innovator in kidney care and vital organ support, today announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis (HF HD). The study, “Survival of expanded hemodialysis and high-flux hemodialysis patients in Colombia: a cohort study,” was presented at the 61st Congress of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress, May 23-26.
Baxter to Present at Jefferies 2024 Global Healthcare Conference
Baxter International Inc. (
NYSEBAX), a global medtech leader, will present at the Jefferies 2024 Global Healthcare Conference on Wednesday, June 5, 2024. Joel Grade, Baxter’s chief financial officer, is scheduled to present at 9:30 a.m. Eastern Time. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through Monday, December 2, 2024.
Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
Baxter International Inc. (
NYSEBAX), a global medtech leader, announced today the mission and logo for its proposed kidney care and acute therapies company, to be named Vantive.
